Canandaigua National Bank & Trust Co. Acquires Shares of 5,547 Gilead Sciences, Inc. $GILD

Canandaigua National Bank & Trust Co. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,547 shares of the biopharmaceutical company’s stock, valued at approximately $701,000.

A number of other hedge funds have also modified their holdings of GILD. Norges Bank acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $2,617,152,000. Boston Partners bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $517,808,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after acquiring an additional 4,113,999 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.80 billion, above the approximately $7.40 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by double-digit HIV growth and continued momentum in Trodelvy. Gilead Q2 Earnings Beat on HIV and Trodelvy Growth
• Positive Sentiment: Management raised its HIV growth outlook to 9%-10% and lifted its 2026 base-business sales outlook to approximately $29.8 billion-$30.1 billion. Yeztugo, Gilead’s HIV PrEP treatment, generated roughly $1 billion in sales as uptake accelerated. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Needham reaffirmed its Buy rating with a $170 price target, while Cantor Fitzgerald maintained Overweight and a $155 target, indicating potential upside if HIV and oncology growth continues.
• Positive Sentiment: Gilead declared its quarterly dividend of $0.82 per share, supporting the stock’s income appeal. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s full-year EPS outlook improved relative to consensus, but revenue guidance of $30.1 billion-$30.4 billion remained slightly below analysts’ $30.5 billion estimate, reflecting acquisition and research spending.
• Negative Sentiment: The company posted a $6.75-per-share quarterly loss versus $2.01 of earnings a year earlier. Acquisition-related charges and research-and-development costs overshadowed the operating improvement and raised concerns about deeper 2026 losses. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and highlighting pressure from a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies, creating potential reputational and access-related risks in global markets. RBC maintained a Sector Perform rating with a $123 target, below the current valuation.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction is a limited signal because it was scheduled in advance, but it may add to investor caution.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday. Wall Street Zen downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Truist Financial cut their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Stock Down 2.6%

GILD opened at $131.76 on Thursday. The firm’s 50-day simple moving average is $129.54 and its 200-day simple moving average is $136.18. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The firm has a market cap of $163.59 billion, a price-to-earnings ratio of -49.35 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 1.86%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the company posted $2.01 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 82,000 shares of company stock worth $10,641,790. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.